

# Ontario Public Drug Programs Drug Submission Status

---

Generic Name: heparin sodium

Brand Name: Heparin Sodium Injection USP

Strength: 1000 U/mL, 5000 U/mL and 10000 U/mL solutions

Manufacturer: Pfizer Canada Inc.

Indication: For prophylaxis and treatment of venous thrombosis and its extension, prophylaxis and treatment of pulmonary embolism, prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation, prevention of clotting in arterial and heart surgery, prophylaxis and treatment of peripheral arterial embolism, anticoagulant use in blood transfusions, extracorporeal circulation and dialysis procedures and diagnosis and treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation)

Rapid Review: Not Requested

Submission Type:	Date Submission Received:	Date Submission Deemed Complete:	Review Status:	Funding Status:
First Review: (Initial Submission)	05/06/2013	N/A	Withdrawn by manufacturer	File closed

## Rapid Review:

Details of the Rapid Review process can be found at:

[Rapid Review Process](#)

## Review Status:

- Screening - Ministry is screening the manufacturer's submission to ensure all regulatory and policy requirements have been met in order to proceed with the drug review.
- Submission incomplete - Manufacturer did not meet the necessary requirements to allow review to proceed.
- Submission complete & under review - Manufacturer met all requirements to proceed with the drug review, and evaluation of the drug submission is underway.
- Committee to Evaluate Drugs (CED) review completed, manufacturer requesting reconsideration – A recommendation was made by the CED, however the manufacturer has submitted or will be submitting additional information.
- Committee to Evaluate Drugs (CED) review completed - A recommendation was made by the CED.
- Ontario Steering Committee for Cancer Drugs (OSCCD) review completed-A recommendation was made by the OSCCD.
- Executive Officer (EO) decision rendered.

## Funding Status:

The Committee to Evaluate Drugs (CED) recommendation and the Executive Officer (EO) decision, if available, can be found at:

[The CED recommendation and the EO decision](#)

Updated: November 26, 2015